Abstract
Vaccines for SARS-CoV-2 currently authorised by the European Medicine Agency are effective, safe and well tolerated in practice. Awareness of rare potential vaccine-related adverse effects (AEs) is important to improve their recognition, management and reporting. An 88-year-old man attended the emergency department with incomplete palsy of the right third cranial nerve 3 days after the first administration of Moderna mRNA-1273 SARS-CoV-2 vaccine. Imaging ruled out a vascular accident and a vaccine AE was hypothesised. Two weeks of oral steroids led to the patient’s recovery, but without evidence of humoral immune response to vaccine. Thus, full immunisation with a dose of Pfizer mRNA-BNT162b2 SARS-CoV-2 vaccine in a different site was attempted. This was uneventful and followed by a robust antibody response. Empirical change of site and vaccine brand may represent a tailored option to obtain full immune protection in selected patients, after vaccine AEs.
Keywords: COVID-19; cranial nerves; peripheral nerve disease; unwanted effects / adverse reactions; vaccination/immunisation.
【저자키워드】 COVID-19, Unwanted effects / adverse reactions, cranial nerves, peripheral nerve disease, Vaccination/immunisation, 【초록키워드】 SARS-CoV-2, Vaccine, mRNA-1273, Antibody Response, SARS-CoV-2 vaccine, Pfizer, Medicine, management, imaging, Awareness, humoral immune response, patients, Moderna, immune protection, Evidence, administration, dose, Safe, adverse effect, Vascular, Effect, European, effective, robust, IMPROVE, selected, the patient, AEs, cranial, hypothesised, oral steroid, 【제목키워드】 SARS-CoV-2, Vaccine, mRNA, humoral immune response, second dose, injection, cranial,